A Prominent Researcher Proposed a Legal Marijuana Program for Patients While Gathering Clinical Data | Research

The takeaway

A senior pharmacologist proposed an interim "compassionate access" program allowing physician-referred patients legal marijuana for six months while collecting quantitative data on four conditions: nausea, wasting, spasticity, and chronic pain.

Read this if you are interested in pragmatic approaches to resolving the tension between medical marijuana access and evidence requirements.

Four conditions prioritized: nausea, wasting, spasticity, chronic pain

What the researchers found

Writing in Drug and Alcohol Dependence, Leo Hollister (a highly respected pharmacologist) proposed a practical solution to the medical marijuana impasse.

The evidence supporting therapeutic marijuana use was insufficient for FDA approval, yet many patients maintained it was necessary for their treatment. His proposed interim solution: a structured 6-month program of legal marijuana availability, similar to the previous "compassionate IND" program, combined with post-marketing surveillance techniques to collect quantitative data.

Four conditions were prioritized for data collection: nausea and vomiting from chemotherapy or other causes, weight loss from debilitating illnesses, spasticity from neurological diseases, and chronic pain syndromes.

This approach would simultaneously provide patient access and generate the structured clinical data needed for regulatory decisions.

Why it matters

This proposal from a respected establishment researcher represented a pragmatic middle ground: providing access while generating evidence. The framework anticipated the structure that many state medical marijuana programs eventually adopted, though without the rigorous data collection component.

The numbers in context

Six-month program proposed. Four priority conditions: nausea/vomiting, wasting, spasticity, chronic pain. Model based on compassionate IND precedent.

How the study worked

Commentary proposing a policy framework combining compassionate access with structured data collection. Referenced the historical compassionate IND model and post-marketing surveillance methodology.

What this study cannot tell us

A policy proposal rather than a research study. The practicality of collecting quantitative data from a compassionate access program was not demonstrated. The proposal did not address regulatory and legal barriers to implementation.

How to read the evidence

A policy proposal from a senior researcher. Provides informed perspective on resolving the access-versus-evidence tension but is not a research study.

When this study was published

Published in 2000. State medical marijuana programs have expanded dramatically, though few have implemented the structured data collection this proposal envisioned.

The bigger picture

While this specific proposal was not adopted, its spirit influenced the development of state medical marijuana programs. The idea of combining access with data collection remains relevant to current debates about how to generate evidence for cannabis therapeutics.

Questions still open

Could a structured access-with-data program work in practice? Would the data collected be rigorous enough for FDA consideration? Why has no jurisdiction implemented this specific model?

Common questions

What was proposed?

A six-month legal marijuana access program for physician-referred patients, combined with structured data collection similar to post-marketing drug surveillance, for four priority conditions.

Was this ever implemented?

Not in its exact form, but state medical marijuana programs adopted similar access principles. The rigorous data collection component was largely not implemented.

Read the original research

An approach to the medical marijuana controversy.

Drug and alcohol dependence, 58(1-2), 3-7

View on PubMed ↗

Citation

Hollister, L E. (2000). An approach to the medical marijuana controversy.. Drug and alcohol dependence, 58(1-2), 3-7.